Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 104 articles:
HTML format



Single Articles


    January 2024
  1. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    PubMed    


  2. TAYLOR TE, Osier F
    Integrating vaccines and monoclonal antibodies into malaria prevention.
    Nat Med. 2024 Jan 10. doi: 10.1038/s41591-023-02745.
    PubMed    


  3. PANT S, Wainberg ZA, Weekes CD, Furqan M, et al
    Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
    Nat Med. 2024 Jan 9. doi: 10.1038/s41591-023-02760.
    PubMed     Abstract available


    December 2023
  4. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Author Correction: Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Dec 22. doi: 10.1038/s41591-023-02772.
    PubMed    


  5. BARNABAS RV, Brown ER, Onono MA, Bukusi EA, et al
    Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.
    Nat Med. 2023 Dec 4. doi: 10.1038/s41591-023-02658.
    PubMed     Abstract available


    November 2023
  6. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Nov 27. doi: 10.1038/s41591-023-02670.
    PubMed     Abstract available


  7. O'LEARY K
    A new, affordable HPV vaccine.
    Nat Med. 2023 Nov 13. doi: 10.1038/d41591-023-00095.
    PubMed    


  8. SCHOMMERS P, Kim DS, Schlotz M, Kreer C, et al
    Dynamics and durability of HIV-1 neutralization are determined by viral replication.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02582.
    PubMed     Abstract available


  9. CHEHRAZI-RAFFLE A, Budde LE, Pal SK
    Boosting CAR T cells with anti-tumor mRNA vaccines.
    Nat Med. 2023 Nov 6. doi: 10.1038/s41591-023-02623.
    PubMed    


    October 2023
  10. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Oct 24. doi: 10.1038/s41591-023-02648.
    PubMed    


  11. MACKENSEN A, Haanen JBAG, Koenecke C, Alsdorf W, et al
    CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
    Nat Med. 2023 Oct 23. doi: 10.1038/s41591-023-02612.
    PubMed     Abstract available


    September 2023
  12. GRASSL N, Poschke I, Lindner K, Bunse L, et al
    A H3K27M-targeted vaccine in adults with diffuse midline glioma.
    Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555.
    PubMed     Abstract available


    August 2023
  13. CHALKIAS S, Whatley JL, Eder F, Essink B, et al
    Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
    Nat Med. 2023 Aug 31. doi: 10.1038/s41591-023-02517.
    PubMed     Abstract available


  14. BRANCHE AR, Rouphael NG, Diemert DJ, Falsey AR, et al
    Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02503.
    PubMed     Abstract available


  15. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    


  16. JOHNSON B
    GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials.
    Nat Med. 2023 Aug 7. doi: 10.1038/d41591-023-00069.
    PubMed    


    July 2023
  17. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A
    Community-engaged Mpox vaccination provides lessons for equitable health care in the United States.
    Nat Med. 2023 Jul 19. doi: 10.1038/s41591-023-02447.
    PubMed    


  18. BARNES E, Goodyear CS, Willicombe M, Gaskell C, et al
    SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02414.
    PubMed     Abstract available


  19. BERKLEY S
    The poorest and most vulnerable communities should be the first to be vaccinated.
    Nat Med. 2023;29:1596.
    PubMed    


    June 2023

  20. Precision medicine meets cancer vaccines.
    Nat Med. 2023;29:1287.
    PubMed    


    May 2023
  21. VAN DER KLAAUW AA, Horner EC, Pereyra-Gerber P, Agrawal U, et al
    Accelerated waning of the humoral response to COVID-19 vaccines in obesity.
    Nat Med. 2023 May 11. doi: 10.1038/s41591-023-02343.
    PubMed     Abstract available


    March 2023
  22. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Author Correction: Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2023 Mar 27:1. doi: 10.1038/s41591-023-02303.
    PubMed    


  23. STAMM TA, Partheymuller J, Mosor E, Ritschl V, et al
    Determinants of COVID-19 vaccine fatigue.
    Nat Med. 2023 Mar 27. doi: 10.1038/s41591-023-02282.
    PubMed     Abstract available


  24. LIPSCHUETZ M, Guedalia J, Cohen SM, Sompolinsky Y, et al
    Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization.
    Nat Med. 2023 Mar 23. doi: 10.1038/s41591-023-02270.
    PubMed     Abstract available


  25. KHOURY DS, Docken SS, Subbarao K, Kent SJ, et al
    Predicting the efficacy of variant-modified COVID-19 vaccine boosters.
    Nat Med. 2023 Mar 2. doi: 10.1038/s41591-023-02228.
    PubMed     Abstract available


    February 2023
  26. GRANT R, Sacks JA, Abraham P, Chunsuttiwat S, et al
    When to update COVID-19 vaccine composition.
    Nat Med. 2023 Feb 20. doi: 10.1038/s41591-023-02220.
    PubMed    


  27. CARVALHO T
    mRNA vaccine effective against RSV respiratory disease.
    Nat Med. 2023 Feb 15. doi: 10.1038/d41591-023-00017.
    PubMed    


    January 2023
  28. SAGY YW, Zucker R, Hammerman A, Markovits H, et al
    Real-world effectiveness of a single dose of mpox vaccine in males.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02229.
    PubMed     Abstract available


  29. WANG G, Yao Y, Wang Y, Gong J, et al
    Determinants of COVID-19 vaccination status and hesitancy among older adults in China.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02241.
    PubMed     Abstract available


  30. O'LEARY K
    Cash rewards for vaccination.
    Nat Med. 2023 Jan 26. doi: 10.1038/d41591-023-00011.
    PubMed    


  31. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Jan 18. doi: 10.1038/s41591-023-02219.
    PubMed     Abstract available


  32. LAZARUS JV, Wyka K, White TM, Picchio CA, et al
    A survey of COVID-19 vaccine acceptance across 23 countries in 2022.
    Nat Med. 2023 Jan 9. doi: 10.1038/s41591-022-02185.
    PubMed     Abstract available


  33. OGONGO P, Ernst JD
    Finding antigens for TB vaccines: the good, the bad and the useless.
    Nat Med. 2023 Jan 5. doi: 10.1038/s41591-022-02123.
    PubMed    


    December 2022
  34. KURHADE C, Zou J, Xia H, Liu M, et al
    Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster.
    Nat Med. 2022 Dec 6. doi: 10.1038/s41591-022-02162.
    PubMed     Abstract available


  35. O'LEARY K
    The next generation of COVID-19 vaccines.
    Nat Med. 2022;28:2450.
    PubMed    


    November 2022
  36. O'LEARY K
    A universal flu vaccine on the horizon.
    Nat Med. 2022 Nov 30. doi: 10.1038/d41591-022-00113.
    PubMed    



  37. Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic.
    Nat Med. 2022 Nov 4. pii: 10.1038/s41591-022-02065.
    PubMed    


  38. CARVALHO T
    Intranasal COVID-19 vaccine fails to induce mucosal immunity.
    Nat Med. 2022 Nov 3. pii: 10.1038/d41591-022-00106.
    PubMed    


    October 2022
  39. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02064.
    PubMed     Abstract available


  40. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed     Abstract available


  41. SCHEAFFER SM, Lee D, Whitener B, Ying B, et al
    Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Nat Med. 2022 Oct 20. pii: 10.1038/s41591-022-02092.
    PubMed     Abstract available


  42. ZAECK LM, Lamers MM, Verstrepen BE, Bestebroer TM, et al
    Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Nat Med. 2022 Oct 18. pii: 10.1038/s41591-022-02090.
    PubMed     Abstract available


  43. MENTZER AJ, O'Connor D, Bibi S, Chelysheva I, et al
    Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02078.
    PubMed     Abstract available


  44. BHATTACHARYA D, Victora GD
    Boosting with updated COVID-19 mRNA vaccines.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02048.
    PubMed    


  45. CHALKIAS S, Eder F, Essink B, Khetan S, et al
    Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02031.
    PubMed     Abstract available


    September 2022
  46. CARVALHO T
    mRNA vaccines boost BioNTech's CAR T cell therapy.
    Nat Med. 2022 Sep 1. pii: 10.1038/d41591-022-00091.
    PubMed    


    August 2022
  47. PALMER CD, Rappaport AR, Davis MJ, Hart MG, et al
    Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2022;28:1619-1629.
    PubMed     Abstract available


    July 2022
  48. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.
    PubMed    


  49. JARA A, Undurraga EA, Zubizarreta JR, Gonzalez C, et al
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.
    Nat Med. 2022;28:1377-1380.
    PubMed     Abstract available


    June 2022
  50. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    PubMed    


  51. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    PubMed     Abstract available


    May 2022
  52. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.
    PubMed    


  53. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.
    PubMed    


  54. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    PubMed     Abstract available


  55. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    PubMed     Abstract available


    April 2022
  56. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.
    PubMed    


  57. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    PubMed     Abstract available


  58. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    PubMed     Abstract available


  59. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    PubMed     Abstract available


    March 2022
  60. WEBSTER P
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.
    PubMed    


  61. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    PubMed     Abstract available


  62. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    PubMed    


  63. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    PubMed     Abstract available


  64. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    PubMed     Abstract available


    February 2022
  65. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    PubMed     Abstract available


  66. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    PubMed     Abstract available


  67. VALKENBURG SA, Poon LLM
    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.
    PubMed    


  68. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    PubMed     Abstract available


  69. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    PubMed     Abstract available


  70. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.
    PubMed    


  71. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    PubMed     Abstract available


  72. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    PubMed     Abstract available


    January 2022
  73. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    PubMed     Abstract available


  74. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    PubMed     Abstract available


  75. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    PubMed     Abstract available


  76. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    PubMed     Abstract available


  77. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    PubMed     Abstract available


  78. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    PubMed     Abstract available


  79. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.
    PubMed    


  80. ETIENNE CF
    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.
    PubMed    


    December 2021
  81. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    PubMed     Abstract available


  82. ADEPOJU P
    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.
    PubMed    



  83. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    PubMed    


  84. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.
    PubMed    


  85. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    PubMed    


  86. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available


  87. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available


  88. VAN KERKHOVE MD
    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.
    PubMed    


  89. WEBSTER P
    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.
    PubMed    


  90. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.
    PubMed    


  91. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.
    PubMed    


    November 2021
  92. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.
    PubMed    


  93. O'LEARY K
    An mRNA vaccine against tick bites.
    Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.
    PubMed    


  94. JUNO JA, Wheatley AK
    Boosting immunity to COVID-19 vaccines.
    Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.
    PubMed    


  95. O'LEARY K
    HPV vaccines beat cervical cancer.
    Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.
    PubMed    


  96. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed     Abstract available


  97. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    PubMed     Abstract available


  98. FENG S, Phillips DJ, White T, Sayal H, et al
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:2032-2040.
    PubMed     Abstract available


    October 2021
  99. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
    PubMed     Abstract available


  100. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
    Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
    PubMed     Abstract available


  101. ALI M, Khan J, Ahmad N, Khan H, et al
    COVID-19 vaccination gives hope to eradicate polio.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.
    PubMed    


    September 2021
  102. O'LEARY K
    Low-dose mRNA vaccination measures up.
    Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.
    PubMed    


  103. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
    Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
    Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
    PubMed     Abstract available


  104. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
    Southeast Asia is an emerging hotspot for COVID-19.
    Nat Med. 2021;27:1495-1496.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.